The impact of the timing of adjuvant treatment initiation in patients with upfront resection of pancreatic cancer
While adjuvant chemotherapy in patients with resectable PDAC is associated with improved OS compared to no adjuvant therapy, it is worth considering that those who are well enough to receive chemotherapy inherently have better prognoses. Importantly, the survival association persists regardless of the timing of chemotherapy initiation, suggesting that late administration of adjuvant chemotherapy may still be beneficial in appropriately selected patients.
Authors
- Kevin Sullivan (ORCID: https://orcid.org/0000-0001-9147-0988)
- Sydney McManus
- Denise Danos (ORCID: https://orcid.org/0000-0001-6256-0861)
- Omeed Moaven (ORCID: https://orcid.org/0000-0002-0560-0457)
- Sanchit Sachdeva (ORCID: https://orcid.org/0009-0001-0976-4336)
- Bolni Marius Nagalo (ORCID: https://orcid.org/0000-0002-2173-7912)
- Aimée Galatas (ORCID: https://orcid.org/0009-0007-4849-2234)
- Sarah Hemelt
Institutions
- Louisiana State University (US)
- Louisiana State University Health Sciences Center New Orleans (US)
- University of Arkansas for Medical Sciences (US)
Publication Details
- Journal
- Surgical Oncology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1016/j.suronc.2025.102329
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05